

Josee-Lyne Ethier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7521188/publications.pdf>

Version: 2024-02-01

19
papers

1,045
citations

932766

10
h-index

839053

18
g-index

19
all docs

19
docs citations

19
times ranked

2128
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research</i> , 2017, 19, 2.	2.2	457
2	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 53, 120-127.	3.4	178
3	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 145, 584-594.	0.6	85
4	Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 147, 158-166.	0.6	71
5	Perceived Barriers to Goals of Care Discussions With Patients With Advanced Cancer and Their Families in the Ambulatory Setting. <i>Journal of Palliative Care</i> , 2018, 33, 125-142.	0.4	53
6	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2017, 77, 40-47.	1.3	52
7	Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2015, 33, 100-106.	0.8	47
8	Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2018, 30, 215-224.	0.6	28
9	Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. <i>PLoS ONE</i> , 2015, 10, e0122735.	1.1	14
10	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, e212140.	3.4	12
11	The needs of gynecological cancer survivors at the end of primary treatment: A scoping review and proposed model to guide clinical discussions. <i>Patient Education and Counseling</i> , 2022, 105, 1761-1782.	1.0	11
12	A systematic review and quality appraisal of international guidelines for early breast cancer systemic therapy: Are recommendations sensitive to different global resources?. <i>Breast</i> , 2015, 24, 309-317.	0.9	7
13	The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 547-553.	0.7	7
14	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. <i>European Journal of Cancer</i> , 2021, 149, 117-127.	1.3	7
15	The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 307-313.	1.6	6
16	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II-IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103324.	2.0	6
17	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II-IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. <i>Current Oncology</i> , 2022, 29, 231-242.	0.9	3
18	Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer. <i>Current Oncology Reports</i> , 2017, 19, 15.	1.8	1

#	ARTICLE	IF	CITATIONS
19	The role of cediranib in ovarian cancer: current status and further investigation. Expert Opinion on Orphan Drugs, 2016, 4, 855-865.	0.5	0